by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Semorinemab, an anti-tau monoclonal antibody, was assessed in two Phase II trials for Alzheimer’s disease (AD). Plasma and cerebrospinal fluid (CSF) biomarkers provided insights into the drug’s potential mechanism of action. METHODS...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract Dementia prevention in Africa is critically underexplored, despite the continent’s high prevalence of modifiable risk factors. With a predominantly young and middle-aged population, Africa presents a prime opportunity to implement evidence-based...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION The Health Equity Scholars Program (HESP) addresses the critical need for a diverse, culturally competent workforce to study and treat older adults from underrepresented populations (URPs) with Alzheimer’s disease and related dementias...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is the most common form of dementia in the elderly. Given that AD neuropathology begins decades before symptoms, there is a dire need for effective screening tools for early detection of AD to facilitate early...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract BACKGROUND Limited research has explored the effect of cardiovascular risk and amyloid interplay on cognitive decline in East Asians. METHODS Vascular burden was quantified using Framingham’s General Cardiovascular Risk Score (FRS) in 526 Korean Brain...
by Clinical Neuropsychologist | Thursday, November 7, 2024 | Dementia
Abstract INTRODUCTION Factors responsible for the deposition of pathological tau in the brain are incompletely understood. This study links macroscale tau deposition in the human brain to cerebrospinal fluid (CSF) flow dynamics using resting-state functional magnetic...
